New findings presented at AIDS 2020: Virtual indicate that a PrEP regimen containing this long-acting injectable drug demonstrated superiority to daily oral tenofovir/emtricitabine in preventing HIV among...
The Centers for Disease Control and Prevention has released guidance on what to consider when evaluating adolescents for pre-exposure prophylaxis for the prevention of HIV.
The FDA has approved a new option for HIV-1 pre-exposure prophylaxis to reduce HIV-1 infection risk from sex, excluding in those who have receptive vaginal sex.
In his session as IAS 2019, Myron Cohen, MD, discussed new long-acting injectables for HIV prevention and the ongoing trials that will determine the efficacy of each.
The impact of tenofovir-containing pre-exposure prophylaxis on bone mineral density may vary depending on an individual’s adherence. Authors of a new study assessed the effect of the only FDA-approved PrEP...
Researchers from Australia investigated the incidence of and behavioral risk factors associated with STIs, as well as the changes in STI incidence after preexposure prophylaxis initiation.
For the first time, the US Preventive Services Task Force has made recommendations for all at-risk populations of HIV infection to receive PrEP therapy. To see which populations are included in this...
